Effects of corticosteroid plus long-acting beta2-agonist on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice
© The Author(s). 2017
Received: 3 September 2016
Accepted: 3 January 2017
Published: 17 January 2017
Airway viral infections cause the exacerbations of asthma and chronic obstructive pulmonary disease. PD-L1, also known as B7-H1, is an immune-checkpoint molecule that plays a role in an escape mechanism of viruses from the host immune systems. This escape may be associated with the persistence of viral infection and the exacerbation of the underlying diseases. In a study in vitro, we have shown that corticosteroids plus long-acting beta2-agonists (LABAs) attenuate the upregulation of PD-L1 on airway epithelial cells stimulated with an analog of viral double-stranded RNA, polyinosinic-polycytidylic acid (poly I:C). To address its biological relevance in vivo, we investigated the effect of corticosteroid plus LABA on the expression of PD-L1 in double-stranded RNA-induced lung inflammation in mice.
Mice were intratracheally administered with poly I:C. The expression of PD-L1 on the lung cells was assessed by flow cytometry and inflammation was assessed for bronchoalveolar lavage fluid (BALF). Independent as well as combination effects of ciclesonide and indacaterol were examined.
Administration of low dose poly I:C upregulated the expression of PD-L1, induced neutrophilia and increased keratinocyte-derived chemokine (KC), macrophage inflammatory protein-1β (MIP-1β), and IL-6 in BALF. The upregulation of PD-L1, neutrophilic inflammation and increase of KC were suppressed by ciclesonide plus indacaterol, but not by either when administered independently. Although the upregulation of PD-L1 by high dose poly I:C was suppressed by ciclesonide plus indacaterol, neutrophilia and increased KC, MIP-1β, and IL-6 in BALF were not attenuated.
Ciclesonide plus indacaterol attenuate double-stranded RNA-induced upregulation of PD-L1 in the lungs.
KeywordsAsthma Viral infection Lung inflammation Corticosteroid Long-acting beta2-agonist
Viral airway infections, such as rhinovirus, respiratory syncytial virus (RSV), human metapeumovirus, and influenza virus, frequently cause the exacerbation of inflammatory airway diseases including asthma and chronic obstructive pulmonary disease (COPD) [1–3]. These viruses possess single-stranded (ss) RNA as their own genome. Influenza virus has a unique tri-phosphate-ended double-stranded (ds) RNA-like structure at the 5’terminal of genomic ssRNA. Rhinovirus, RSV, and human metapeumovirus generate dsRNA in their host cells. These dsRNAs activate innate immune responses through their binding to Toll-like receptor 3 (TLR3) and the family of RNA helicase, namely, the retinoic acid-inducible gene I (RIG-I) and the melanoma differentiation-associated gene 5 (Mda5) [4–6]. TLR3 recognizes viral dsRNA and a synthetic analog of dsRNA, polyinocinic polycytidilic acid (poly I:C), in the endosome, while RIG-I and Mda5 recognize dsRNA in the cytoplasm. RIG-I recognizes dsRNA of RSV, human metapeumovirus and influenza virus. Mda5 recognizes dsRNA of rhinovirus and poly I:C. Subsequent signaling leads to adapted antiviral immunity.
Adapted immune responses are initiated by the interactions between antigen-presenting cells and T cells. These interactions are characterized by the binding of a variety of costimulatory and coinhibitory molecules, including B7-family molecules, and their putative receptors . PD-L1, also named as B7-H1, belongs to the B7 family and shares its receptor, programmed death-1 (PD-1), with PD-L2, also named as B7-DC. PD-1 is induced in T cells and B cells during their activation, and its ligation to PD-L1 results in the inhibition of the activated status. PD-L1, PD-L2 and PD-1 have been known as immune-checkpoint molecules in tumor and infection immunity . Previous studies showed that the blockade of the PD-L1/PD-1 pathway restored the function of virus-specific cytotoxic T lymphocytes (CTLs) and decreased the viral load, suggesting that PD-L1 upregulation causes CTL exhaustion and then impairs virus eradication [9–11]. The airway epithelial cells are targeted by viruses for their replication. Human epithelial cells constitutively expressed a low level of PD-L1 and poly I:C stimulation upregulated the expression of PD-L1 [12–14]. Given a high expression of PD-1 on virus-specific CTLs, dsRNA-induced upregulation of PD-L1 may prevent the infected cells from attack by CTLs, thereby facilitating the spread of a virus around the neighboring cells . Antigen-presenting cells, particularly dendritic cells, are other important cells in the anti-viral immune defense. Virus- or dsRNA-stimulated dendritic cells trigger an array of anti-viral innate- and adapted-immune responses . On the other hand, virus and dsRNA upregulates the expression of PD-L1 on dendritic cells, which may compromise the anti-viral immune responses [17, 18].
Inhaled corticosteroids (ICSs) and long-acting beta2-agonists (LABAs) are used worldwide for the treatment of asthma and COPD. Clinical trials showed that the combination of ICSs with LABAs improves symptoms and lung function and reduces exacerbations in subjects with asthma and COPD [19–21]. The mechanism of action for reducing exacerbation has not fully been elucidated. We previously showed that ICSs plus LABAs attenuate the poly IC- or RSV-induced upregulation of PD-L1 on airway epithelial cells in vitro . To address its biological relevance in vivo, we investigated the effect of corticosteroid plus long-acting beta2-agonist on the expression of PD-L1/B7-H1 in dsRNA-induced lung inflammation in mice.
Ciclesonide (CIC) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Indacaterol maleate (IND) was provided from Novartis Pharma AG (Basel, Switzerland). Poly I:C and dimethyl sulfoxide (DMSO) were purchased from SIGMA-ALDRICH (St. Louis, MO, USA). Anti-mouse CD16/CD32 mAb was purchased from BD Biosciences (San Diego, CA, USA). FITC-conjugated mouse anti-keratin 5/8 monoclonal Ab (mAb) was purchased from Progen (Heidelberg, Germany). Biotinylated anti-human PD-L1 mAb and anti-mouse PD-L1 mAb were purchased from eBioscience (San Diego, CA, USA). Streptavidin-phycoerythrin (SAv-PE) conjugate was purchased from BD Biosciences (San Jose, CA, USA).
Culture of airway epithelial cells
The BEAS-2B cell line, derived from human bronchial epithelium transformed by an adenovirus 12-SV-40 virus, was cultured in 6-well plates by using DMEM/F12 containing 10% FBS, penicillin (100 U/ml), and streptomycin (100 ng/ml) at 37 °C with 5% CO2 in humidified air.
Stimulation of cells with dsRNA
When cells reached semi-confluence, they were stimulated by administration of 3 μg/ml poly I:C in the culture medium. After 4 h incubation, they were replaced with a fresh medium. The cells were pretreated with CIC, IND, CIC plus IND or vehicle alone for 2 h before the stimulation. The cells were harvested 24 h after the stimulation.
Male C57BL/6 mice (5–7 weeks old) were purchased from SLC Japan and were housed under specific pathogen-free conditions until the experiments commenced.
Mice were anesthetized with 80 μg/kg dexmetdetomidine i.p., subsequently with inhalation of 3–4% isoflurane. A tracheal cannulation was temporally performed with 20 gauge catheter. To elucidate time courses of PD-L1 expression and airway inflammation induced by poly I:C stimulation, mice were anesthetized and received intratracheal instillation (i.t.) of poly I:C (30 μg, in total volume of 50 μl). At 24, 72, and 168 h after poly I:C stimulation, mice were sacrificed, bronchoalveolar lavage was performed, and then the lungs were collected. Mice received i.t. of poly I:C (3 or 30 μg, in total volume of 50 μl), 4 h after the administration of CIC (3 μg, in total volume of 50 μl) and/or IND (3 μg, in total volume of 50 μl) i.t.. Poly I:C was dissolved in physiological saline before use. CIC and IND were dissolved in DMSO and diluted saline to 6% in final formulation. CIC and IND were used immediately after preparation. Sham-treated mice were used as controls. We provided ethics approval information with protocol ID (A23-048-0 and A25-007-0).
Bronchoalveolar lavage and ELISA
After 24 h of poly I:C administration, mice were sacrificed under a mixture of ketamine and sodium pentobarbital i.p. injection, and their tracheas were cannulated via tracheostomy. The lungs were lavaged with 1 ml of PBS via tracheal cannula. Differential cell counts were performed. Samples were centrifuged at 2000 rpm for 10 min, the supernatants were collected and the concentration of keratinocyte-derived chemokine (KC), macrophage inflammatory protein-1β (MIP-1β) and IL-6 in bronchoalveolar lavage fluid (BALF) were measured using ELISA kit (BioSource, or R&D Systems).
Flow cytometric analysis
For BEAS-2B cell study, 5 × 106 cells were incubated in 100 μl of phosphate-buffered saline (PBS) with 0.5% BSA and 0.02% NaN3 containing biotynilated anti-human PD-L1 mAb at room temperature for 30 min. The samples were thoroughly washed and suspended in SAv-PE conjugate for 20 min. After washing with PBS/0.5% BSA/0.02% NaN3, the cells were fixed with 4% paraformaldehyde for 20 min. For in vivo study, lungs were cut and minced. PBS containing 2 mM dithiothreitol, 5 mM EDTA was added to the minced lungs and incubated for 40 min at 37 °C. The samples were filtered through a 70 μm pores size nylon cell strainer. The single-cell suspensions were washed with complete PBS, and the erythrocytes were lysed with an NH4Cl-Tris buffer. Cells were suspended in PBS with 0.5% BSA and 0.02% NaN3, and 0.02%EDTA, referred as a washing buffer. Cells were preincubated with anti-mouse CD16/CD32 mAb to prevent nonspecific binding via FcγR. For the dual-color flow cytometry, cells were incubated with FITC-conjugated anti-keratin 5/8 mAb for 30 min, followed by the addition of biotinylated anti-mouse PD-L1 mAb for 30 min. The samples were washed with the washing buffer and suspended in SAv-PE conjugate for 20 min. Cells were thoroughly washed, fixed with 4% paraformaldehyde, and flow cytometric analysis was performed using a FACSCalibur with CellQuest software (BD Biosciences, CA, USA). Thirty thousand events were acquired in a list mode with debris excluded by the forward-scatter threshold. The mean fluorescence intensity (MFI) was compared with control staining using an irrelevant isotype-matched mAb.
Values were expressed as the means ± SEM. Differences among groups were analyzed using an ANOVA followed by the multiple comparison test of Tukey-Kramer. JMP Pro 11 software was used for statistical analysis. P-values less than 0.05 were accepted as statistically significant.
In the present study, combination effects of CIC/IND were examined for the expression of PD-L1 and inflammation in dsRNA-induced models of airway viral infection. We postulated that two doses of poly I:C could reflect light and heavy infection mainly based on RSV-infection in humans. It is well known that a proportion of infants with RSV infection develop severe bronchiolitis whereas a majority of RSV-infected infants and healthy adults have limited disease such as cold-like symptoms. Although the precise mechanisms explaining those different patterns of outcomes remain uncertain, several studies suggested that neutrophilic inflammation may be readout of viral loads [26, 27]. A part of them may be derived from net burden of viral dsRNA. There have been several studies that used poly I:C in order to mimic airway viral infection [28–30]. These studies showed that a single topical administration of poly I:C to the respiratory tracts dose-dependently induced neutrophilic airway inflammation and increased KC, MIP-1β, and IL-6 in BALF, which was also confirmed in the present study. In the experiments of poly I:C (3 μg i.t.) as a model of light infection, the upregulation of PD-L1, neutrophilic inflammation and the elevation of KC were significantly suppressed by CIC plus IND, but not by CIC or IND alone. Given that KC is a strong chemoattractant for neutrophils, the reduction of neutrophilic inflammation may be the outcome of reduced production of KC by CIC plus IND. In the experiments of poly I:C (30 μg) as a model of heavy infection, the upregulation of PD-L1 was also suppressed by CIC plus IND but the neutrophilic inflammation and the productions of KC, MIP-1β, and IL-6 in BALF were not attenuated. These results suggest that the suppression of PD-L1 by CIC plus IND was not due to reduced impact of poly I:C-induced neutrophilic inflammation. We did not measure PD-1 because methodological limitation in this study. The use of poly I:C, a synthetic double-stranded RNA, may mimic virus-induced innate immune responses but not induce viral antigen-induced adoptive immune responses including viral antigen-specific CTLs expressing PD-1. We also did not measure PD-L2 because pathophysiological roles of PD-L2 in airway viral infection remain uncertain.
The synergy of CIC/IND may be partly explained by its direct effect on epithelial cells according to the results obtained from the study in vitro using cultured BEAS-2B cells. In the study in vivo, the expression of PD-L1 was assessed for keratin 5/8 mAb-positive cells that include epithelial cells and myeloid-derived inflammatory cells. The myeloid-derived dendritic cells increase their expression of PD-L1 in response to dsRNA [17, 18, 31]. Recent investigations revealed that there are different neutrophil subsets in mice and humans [32–34]. A CD16high/CD62Ldim subset is known to suppress lymphocyte proliferation and induces lymphocyte apoptosis, through PD-L1 expression on this subset [33, 34]. These studies raise a possibility that suppression of PD-L1 expression in CIC/IND-treated mice may be partly due to downregulation of PD-L1 on the neutrophil subset.
Although there has been no literature showing the effect of ICS plus LABA on virus-induced upregulation of PD-L1 in vivo, a previous study showed that treatment of RSV-infected mice with fluticasone propionate plus salmeterol resulted in a 50% decrease of RSV titer in the lung and a reduction in neutrophils compared to either of drugs alone . The decrease of viral titer by ICS plus LABA may affect the expression status of PD-L1 in real viral infection. The presented model has a technical limitation. Viruses can amplify themselves within several days of initial airway infection, whereas poly I:C can be eliminated by the lung soon after administration, making it difficult to elucidate sub-chronic immune responses to viral infection.
It is important to consider the outcome of PD-L1 suppression by ICS/LABA on airway viral infection. The upregulation of PD-L1 on epithelial cells render virus-specific CTLs to fail to eradicate virus-infected epithelial cells [14, 15]. The upregulation of PD-L1 on myeloid-derived inflammatory cells, particularly the neutrophil subset described above, suppress lymphocyte proliferation, induce lymphocyte apoptosis, and then compromise anti-pathogen host defense [34, 36]. With this regard, ICS/LABA treatment may be beneficial for earlier virus eradication. On the other hand, a recent study reported that PD-L1 upregulation on a subset of dendritic cells prevents excessive immune reaction triggered by RSV . Several studies provided novel information regarding the expression kinetics of PD-L1 in microorganism infections. One study showed that influenza virus-induced expression of PD-L1 was decreased on macrophages in subjects with COPD compared with those in control subjects . The other study showed that early-life Chlamydia respiratory infection-induced PD-L1 promoted severe inflammation during inflammation, permanent reductions in lung function, and the development of more severe allergic airway disease in later life in a mouse model of lung inflammation . As for human rhinovirus, the most common virus linked to exacerbation of asthma and COPD, human airway epithelial cells infected with the virus upregulated the expression of PD-L1 . These studies suggest the diversity in the expression kinetics of PD-L1 and then the impacts of infection-induced upregulation of PD-L1 may be different among underlying diseases. Further investigation is required to discriminate PD-L1-expressing cell types in the lungs and to evaluate ICS/LABA on PD-L1 expression on each cell type.
Administration of poly I:C upregulated the expression of PD-L1, induced neutrophilia and increased KC, MIP-1β and IL-6 in BALF. The upregulation of PD-L1, neutrophilic inflammation and increase of KC were suppressed by ciclesonide plus indacaterol, but not by either when used independently of each other.
Bronchoalveolar lavage fluid
Chronic obstructive pulmonary disease
Cytotoxic T lymphocytes
The mean fluorescence intensity
Macrophage inflammatory protein-1β
- poly I:C:
We would like to thank Mayu Matsuo (Kyushu University) for her technical assistance.
This study was supported in part by a grant-in-aid for scientific research from the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 24591132, Culture of Japan and by the National Institute of Biomedical Innovation, Japan, Novartis Pharma K.K., and provision of indacaterol: Novartis Pharma AG, Switzerland.
Availability of data and materials
The data are all presented in the manuscript.
SH and KM designed all the experiments, conducted the experiments and the statistical analysis, and wrote the initial drafts of the manuscript. KT, SF, and KK aided with in vitro experiments. KT and NS aided with in vivo experiments. HI and YN advised the designing of experiments and helped with writing the manuscript. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
All experimental procedures were approved by the animal research ethics committee of Kyushu University (reference number: A23-048-1 and A25-007-0).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Jackson DJ, Sykes A, Mallia P, et al. Asthma exacerbations: origin, effect, and prevention. J Allergy Clin Immunol. 2011;128:1165–74.View ArticlePubMedGoogle Scholar
- Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax. 2006;61:250–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Matsumoto K, Inoue H. Viral infections in asthma and COPD. Respir Investig. 2014;52:92–100.View ArticlePubMedGoogle Scholar
- Alexopoulou L, Holt AC, Medzhitov R, et al. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001;413:732–8.View ArticlePubMedGoogle Scholar
- Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol. 2004;5:730–7.View ArticlePubMedGoogle Scholar
- Kato H, Takeuchi O, Sato S, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101–5.View ArticlePubMedGoogle Scholar
- Ceeraz S, Nowak EC, Noelle RJ. B7 family checkpoint regulators in immune regulation and disease. Trends Immunol. 2013;34:556–63.View ArticlePubMedGoogle Scholar
- Pauken KE, Wherry EJ. Overcoming T cell exhaution in infection and cancer. Trends Imuunol. 2015;36:265–76.View ArticleGoogle Scholar
- Iwai Y, Terawaki S, Ikegawa M, et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J Exp Med. 2003;198:39–50.View ArticlePubMedPubMed CentralGoogle Scholar
- Barber DL, Wherry EJ, Masopust D, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–7.View ArticlePubMedGoogle Scholar
- Erickson JJ, Gilchuk P, Hastings AK, et al. Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Invest. 2012;122:2967–82.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsuda M, Matsumoto K, Inoue H, et al. Expression of B7-H1 and B7-DC on the airway epithelium is enhanced by double-stranded RNA. Biochem Biophys Res Commun. 2005;330:263–70.View ArticlePubMedGoogle Scholar
- Heinecke L, Proud D, Sanders S, et al. Induction of B7-H1 and B7-DC expression on airway epithelial cells by the Toll-like receptor 3 agonist double-stranded RNA and human rhinovirus infection: In vivo and in vitro studies. J Allergy Clin Immunol. 2008;121:1155–60.View ArticlePubMedPubMed CentralGoogle Scholar
- Telcian AG, Laza-Stanca V, Edwards MR, et al. RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. J Infect Dis. 2011;203:85–94.View ArticlePubMedPubMed CentralGoogle Scholar
- McNally B, Ye F, Willette M, et al. Local blockage of epithelial PDL-1 in the airways enhances T cell function and viral clearance during influneza virus infection. J Virol. 2013;87:12916–24.View ArticlePubMedPubMed CentralGoogle Scholar
- Kim TH, Lee HK. Differential roles of lung dendritic cell subsets against respiratory virus infection. Immune Netw. 2014;14:128–37.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen L, Zhang Z, Chen W, et al. B7-H1 up-regulation on myeloid dendritic cells significantly suppresses T cell immune function in patients with chronic hepatitis B. J Immunol. 2007;178:6634–41.View ArticlePubMedGoogle Scholar
- Yao S, Jiang L, Moser EK, et al. Control of pathogenic effector T-cell activities in situ by PD-L1 expression on respiratory inflammatory dendritic cells during respiratory syncytial virus infection. Mucosal Immunol. 2015;8:746–59.View ArticlePubMedGoogle Scholar
- Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med. 1997;337:1405–11.View ArticlePubMedGoogle Scholar
- O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392–7.View ArticlePubMedGoogle Scholar
- Calverley PMA, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–89.View ArticlePubMedGoogle Scholar
- Kan-o K, Matsumoto K, Inoue H, et al. Corticosteroids plus long-acting β2-agonists prevent double-stranded RNA-induced upregulation of B7-H1 on airway epithelium. Int Arch Allergy Immunol. 2013;160:27–36.View ArticlePubMedGoogle Scholar
- Levine RA, Hopman T, Guo L, et al. Induction of retinoblastoma gene expression during terminal growth arrest of a conditionally immortalized fetal rat lung epithelial cell line and during fetal lung maturation. Exp Cell Res. 1998;239:264–76.View ArticlePubMedGoogle Scholar
- Na N, Chandel NS, LItvan J, et al. Mitocohodrial reactive oxygen species are required for hypoxia-induce degradation of keratin intermediate filaments. FASEB J. 2010;24:799–809.View ArticlePubMedGoogle Scholar
- Medina A, Kilani RT, Carr N, et al. Transdifferentiation of peripheral blood mononuclear cell into epithelial-like cells. Am J Pathol. 2007;171:1140–52.View ArticlePubMedPubMed CentralGoogle Scholar
- Yasui K, Baba A, Iwasaki Y, et al. Neutrophil-mediated inflammation in respiratory syncytial viral bronchiolitis. Pediatr Int. 2005;47:190–5.View ArticlePubMedGoogle Scholar
- Geerdink RJ, Pillay J, Meyaard L, et al. Neutrophil in respiratory syncytial virus infection: A target for asthma prevention. J Allergy Clin Immunol. 2015;136:838–47.View ArticlePubMedGoogle Scholar
- Traynor TR, Majde JA, Bohnet SG, et al. Intratracheal double-stranded RNA plus interferon-g: A model for analysis of the acute phase response to respiratory viral infections. Life Sci. 2004;74:2563–76.View ArticlePubMedGoogle Scholar
- Harris P, Sridhar S, Peng R, et al. Double-stranded RNA induces molecular and inflammatory signatures that are directly relevant to COPD. Mucosal Immunol. 2013;6:474–84.View ArticlePubMedGoogle Scholar
- Clarke DL, Davis NHE, Majithiya JB, et al. Developpment of a mouse model mimicking key astpects of a viral asthma exacerbation. Clin Sci. 2014;126:567–80.View ArticlePubMedGoogle Scholar
- Matsumoto K, Kan-o K, Eguchi-Tsuda M, et al. Essential role of B7-H1 in double-stranded RNA-induced augmentation of asthma phenotype in mice. Am J Respir Cell Mol Biol. 2011;45:31–9.View ArticlePubMedGoogle Scholar
- McNab FW, Berry MP, Graham CM, et al. Programmed death ligand 1 is over-expressed by neutrophils in the blood of patients sith active tuberculosis. Eur J Immunol. 2011;41:1941–7.View ArticlePubMedPubMed CentralGoogle Scholar
- de Klejin S, Langereis JD, Leentjens J, et al. IFN-γ-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One. 2013;28:e72249.View ArticleGoogle Scholar
- Wang JF, Li JB, Zhao YJ, et al. Up-regulation of programmed cell death 1 ligand 1 on neutrophils may be involved in sepsis-induced immunosuppression: an animal study and a prospective case–control study. Anestesiology. 2015;122:852–63.View ArticleGoogle Scholar
- Singam R, Jena PK, Behera S, et al. Combined fluticasone propionate and salmeterol reduces RSV infection more effectively than either of them alone in allergen-sensitized mice. Virol J. 2006;3:32.View ArticlePubMedPubMed CentralGoogle Scholar
- Buddhisa S, Rinchai D, Ato M, et al. Programmed death ligand 1 on Burkholderia pseudomallei-infected human polymorphonuclear neutrophils impairs T cell functions. J Immunol. 2015;194:4413–21.View ArticlePubMedGoogle Scholar
- McKendry RT, Spalluto CM, Burke H, et al. Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 axis. Am J Respir Crit Care Med. 2016;193:642–51.View ArticlePubMedPubMed CentralGoogle Scholar
- Starkey MR, Nguyen DH, Brown AC, et al. Programmed death ligand 1 promotes early-life Chramydia respiratory infection-induced severe allergic airway disease. Am J Respir Cell Mol Biol. 2016;54:493–503.View ArticlePubMedGoogle Scholar